This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
|3D model (Jmol)||Interactive image|
|Molar mass||103.120 g/mol|
|Appearance||white microcrystalline powder|
|Melting point||203.7 °C (398.7 °F; 476.8 K)|
|Boiling point||247.9 °C (478.2 °F; 521.0 K)|
|130 g/100 mL|
|Acidity (pKa)||4.23 (carboxyl), 10.43 (amino)|
|Main hazards||Irritant, Harmful|
|Lethal dose or concentration (LD, LC):|
LD50 (median dose)
|12,680 mg/kg (mouse, oral)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
gamma-Aminobutyric acid (γ-Aminobutyric acid) / / (also called GABA // for short) is the chief inhibitory neurotransmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability throughout the nervous system. In humans, GABA is also directly responsible for the regulation of muscle tone.
Although in chemical terms it is an amino acid (as it has both a primary amine and a carboxylic acid functional group), GABA is rarely referred to as such in the scientific or medical community. By convention the term "amino acid", when used without a qualifier, refers specifically to an alpha amino acid. GABA is not an alpha amino acid, meaning the amino group is not attached to the alpha carbon so it is not incorporated into proteins.[clarification needed]
In vertebrates, GABA acts at inhibitory synapses in the brain by binding to specific transmembrane receptors in the plasma membrane of both pre- and postsynaptic neuronal processes. This binding causes the opening of ion channels to allow the flow of either negatively charged chloride ions into the cell or positively charged potassium ions out of the cell. This action results in a negative change in the transmembrane potential, usually causing hyperpolarization. Two general classes of GABA receptor are known:
- GABAA in which the receptor is part of a ligand-gated ion channel complex
- GABAB metabotropic receptors, which are G protein-coupled receptors that open or close ion channels via intermediaries (G proteins)
Neurons that produce GABA as their output are called GABAergic neurons, and have chiefly inhibitory action at receptors in the adult vertebrate. Medium spiny cells are a typical example of inhibitory central nervous system GABAergic cells. In contrast, GABA exhibits both excitatory and inhibitory actions in insects, mediating muscle activation at synapses between nerves and muscle cells, and also the stimulation of certain glands. In mammals, some GABAergic neurons, such as chandelier cells, are also able to excite their glutamatergic counterparts.
GABAA receptors are ligand-activated chloride channels: when activated by GABA, they allow the flow of chloride ions across the membrane of the cell. Whether this chloride flow is depolarizing (makes the voltage across the cell's membrane less negative), shunting (has no effect on the cell's membrane potential), or inhibitory/hyperpolarizing (makes the cell's membrane more negative) depends on the direction of the flow of chloride. When net chloride flows out of the cell, GABA is depolarising; when chloride flows into the cell, GABA is inhibitory or hyperpolarizing. When the net flow of chloride is close to zero, the action of GABA is shunting. Shunting inhibition has no direct effect on the membrane potential of the cell; however, it reduces the effect of any coincident synaptic input by reducing the electrical resistance of the cell's membrane. Shunting inhibition can "override" the excitatory effect of depolarising GABA, resulting in overall inhibition even if the membrane potential becomes less negative. It was thought that a developmental switch in the molecular machinery controlling concentration of chloride inside the cell changes the functional role of GABA between neonatal and adult stages. As the brain develops into adulthood, GABA's role changes from excitatory to inhibitory. However, this theory of excitatory GABA in developing brain has been questioned and subsequent studies in live neonatal rodents have directly shown GABA to be inhibitory in its action (see next section).
While GABA is an inhibitory transmitter in the mature brain, its actions were thought to be primarily excitatory in the developing brain. The gradient of chloride was reported to be reversed in immature neurons, with its reversal potential higher than the resting membrane potential of the cell; activation of a GABA-A receptor thus leads to efflux of Cl− ions from the cell (that is, a depolarizing current). The differential gradient of chloride in immature neurons was shown to be primarily due to the higher concentration of NKCC1 co-transporters relative to KCC2 co-transporters in immature cells. GABA itself is partially responsible for orchestrating the maturation of ion pumps. GABAergic interneurons mature faster in the hippocampus and the GABA signalling machinery appears earlier than glutamatergic transmission. Thus, GABA was considered the major excitatory neurotransmitter in many regions of the brain before the maturation of glutamatergic synapses.
However, this theory has been questioned based on results showing that in brain slices of immature mice incubated in artificial cerebrospinal fluid (ACSF) (modified in a way that takes into account the normal composition of the neuronal milieu in sucklings by adding an energy substrates alternative to glucose, beta-hydroxybutyrate) GABA action shifts from excitatory to inhibitory mode.
This effect[which?] has been later repeated when other energy substrates, pyruvate and lactate, supplemented glucose in the slices' media. Later investigations of pyruvate and lactate metabolism found that the original results were not due to energy source issues but to changes in pH resulting from the substrates acting as "weak acids". These arguments were later rebutted by further findings showing that changes in pH even greater than that caused by energy substrates do not affect the GABA-shift described in the presence of energy substrate-fortified ACSF and that the mode of action of beta-hydroxybutyrate, pyruvate and lactate (assessed by measurement NAD(P)H and oxygen utilization) was energy metabolism-related. The true nature GABA effect in the developing brain has remained elusive until 2015, when the first study to directly show GABA action in live rodent brain has reported GABA to not be excitatory in its effect even though it slightly depolarised some neurons, confirming the dominance of shunting inhibition. In 2016, another study in live developing brains using optogenetics have shown GABA to be inhibitory, with GABAergic synapse activation leading to a reduction of network activity. That study has also shown that the same technique when used in brain slices instead records excitatory GABA effects, confirming the fact that excitatory GABA is most likely an artefact of in-vitro slice recordings.
In the developmental stages preceding the formation of synaptic contacts, GABA is synthesized by neurons and acts both as an autocrine (acting on the same cell) and paracrine (acting on nearby cells) signalling mediator. The ganglionic eminences also contribute greatly to building up the GABAergic cortical cell population.
GABA also regulates the growth of embryonic and neural stem cells. GABA can inﬂuence the development of neural progenitor cells via brain-derived neurotrophic factor (BDNF) expression. GABA activates the GABAA receptor, causing cell cycle arrest in the S-phase, limiting growth.
Beyond the nervous system
GABAergic mechanisms have been demonstrated in various peripheral tissues and organs including, but not restricted to, the intestine, stomach, pancreas, Fallopian tube, uterus, ovary, testis, kidney, urinary bladder, lung, and liver.
In 2007, an excitatory GABAergic system was described in the airway epithelium. The system activates following exposure to allergens and might participate in the mechanisms of asthma. GABAergic systems have also been found in the testis and in the eye lens.
Structure and conformation
GABA is found mostly as a zwitterion, that is, with the carboxy group deprotonated and the amino group protonated. Its conformation depends on its environment. In the gas phase, a highly folded conformation is strongly favored because of the electrostatic attraction between the two functional groups. The stabilization is about 50 kcal/mol, according to quantum chemistry calculations. In the solid state, a more extended conformation is found, with a trans conformation at the amino end and a gauche conformation at the carboxyl end. This is due to the packing interactions with the neighboring molecules. In solution, five different conformations, some folded and some extended, are found as a result of solvation effects. The conformational flexibility of GABA is important for its biological function, as it has been found to bind to different receptors with different conformations. Many GABA analogues with pharmaceutical applications have more rigid structures in order to control the binding better.
In 1883, gamma-aminobutyric acid (GABA) was first synthesized, and it was first known only as a plant and microbe metabolic product.
Exogenous GABA does not penetrate the blood–brain barrier; it is synthesized in the brain. It is synthesized from glutamate using the enzyme glutamate decarboxylase (GAD) and pyridoxal phosphate (which is the active form of vitamin B6) as a cofactor. This process converts glutamate, the principal excitatory neurotransmitter, into the principal inhibitory neurotransmitter (GABA).
GABA is converted back to glutamate by a metabolic pathway called the GABA shunt.
GABA transaminase enzyme catalyzes the conversion of 4-aminobutanoic acid (GABA) and 2-oxoglutarate (α-ketoglutarate) into succinic semialdehyde and glutamate. Succinic semialdehyde is then oxidized into succinic acid by succinic semialdehyde dehydrogenase and as such enters the citric acid cycle as a usable source of energy.
Drugs that act as allosteric modulators of GABA receptors (known as GABA analogues or GABAergic drugs) or increase the available amount of GABA typically have relaxing, anti-anxiety, and anti-convulsive effects. Many of the substances below are known to cause anterograde amnesia and retrograde amnesia.
In general, GABA does not cross the blood–brain barrier, although certain areas of the brain that have no effective blood–brain barrier, such as the periventricular nucleus, can be reached by drugs such as systemically injected GABA. At least one study suggests that orally administered GABA increases the amount of human growth hormone (HGH). GABA directly injected to the brain has been reported to have both stimulatory and inhibitory effects on the production of growth hormone, depending on the physiology of the individual. Certain pro-drugs of GABA (ex. picamilon) have been developed to permeate the blood–brain barrier, then separate into GABA and the carrier molecule once inside the brain. This allows for a direct increase of GABA levels throughout all areas of the brain, in a manner following the distribution pattern of the pro-drug prior to metabolism.
GABA enhanced the catabolism of serotonin into N-acetylserotonin (the precursor of melatonin) in rats. It is thus suspected that GABA is involved in the synthesis of melatonin and thus might exert regulatory effects on sleep and reproductive functions.
- GABAA receptor ligands.
- Agonists/positive allosteric modulators: ethanol, barbiturates, benzodiazepines, carisoprodol, chloral hydrate, etaqualone, etomidate, glutethimide, kava, methaqualone, muscimol, neuroactive steroids, z-drugs, propofol, skullcap, valerian, theanine, volatile/inhaled anaesthetics.
- Antagonists/negative allosteric modulators: bicuculline, cicutoxin, flumazenil, furosemide, gabazine, oenanthotoxin, picrotoxin, Ro15-4513, thujone, amentoflavone.
- GABAB receptor ligands.
- GABA reuptake inhibitors: deramciclane, hyperforin, tiagabine.
- GABA-transaminase inhibitors: gabaculine, phenelzine, valproate, vigabatrin, lemon balm (Melissa officinalis).
- GABA analogues: pregabalin and gabapentin.
- Others: GABA (itself), L-glutamine, L-theanine, picamilon, progabide.
- GABA receptors
- Spastic diplegia, a GABA deficiency neuromuscular neuropathology
- GABA tea
- GABA analogue
- Succinic semialdehyde dehydrogenase deficiency
- 4-aminobutyrate transaminase (GABA-transaminase) deficiency
- Dawson RM, Elliot DC, Elliot WH, Jones KM, eds. (1959). Data for Biochemical Research. Oxford: Clarendon Press.[page needed]
- Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H (2002). "GABA and GABA receptors in the central nervous system and other organs". In Jeon KW. Int. Rev. Cytol. International Review of Cytology. 213. pp. 1–47. doi:10.1016/S0074-7696(02)13011-7. ISBN 978-0-12-364617-0. PMID 11837891.
- Ffrench-Constant RH, Rocheleau TA, Steichen JC, Chalmers AE (June 1993). "A point mutation in a Drosophila GABA receptor confers insecticide resistance". Nature. 363 (6428): 449–51. Bibcode:1993Natur.363..449F. doi:10.1038/363449a0. PMID 8389005.
- Szabadics J, Varga C, Molnár G, Oláh S, Barzó P, Tamás G (January 2006). "Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits". Science. 311 (5758): 233–235. Bibcode:2006Sci...311..233S. doi:10.1126/science.1121325. PMID 16410524.
- Li K, Xu E (June 2008). "The role and the mechanism of γ-aminobutyric acid during central nervous system development". Neurosci Bull. 24 (3): 195–200. doi:10.1007/s12264-008-0109-3. PMID 18500393.
- Bregestovski P, Bernard C (2012). "Excitatory GABA: How a Correct Observation May Turn Out to be an Experimental Artifact". Frontiers in Pharmacology. 3: 65. doi:10.3389/fphar.2012.00065. PMID 22529813.
- Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R (October 2007). "GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations". Physiol. Rev. 87 (4): 1215–1284. doi:10.1152/physrev.00017.2006. PMID 17928584.
- Ganguly K, Schinder AF, Wong ST, Poo M (May 2001). "GABA itself promotes the developmental switch of neuronal GABAergic responses from excitation to inhibition". Cell. 105 (4): 521–32. doi:10.1016/S0092-8674(01)00341-5. PMID 11371348.
- Rheims S, Holmgren CD, Chazal G, Mulder J, Harkany T, Zilberter T, Zilberter Y (August 2009). "GABA action in immature neocortical neurons directly depends on the availability of ketone bodies". J. Neurochem. 110 (4): 1330–8. doi:10.1111/j.1471-4159.2009.06230.x. PMID 19558450.
- Holmgren CD, Mukhtarov M, Malkov AE, Popova IY, Bregestovski P, Zilberter Y (February 2010). "Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex in vitro". Journal of Neurochemistry. 112 (4): 900–12. doi:10.1111/j.1471-4159.2009.06506.x. PMID 19943846.
- Tyzio R, Allene C, Nardou R, Picardo MA, Yamamoto S, Sivakumaran S, Caiati MD, Rheims S, Minlebaev M, Milh M, Ferré P, Khazipov R, Romette JL, Lorquin J, Cossart R, Khalilov I, Nehlig A, Cherubini E, Ben-Ari Y (January 2011). "Depolarizing actions of GABA in immature neurons depend neither on ketone bodies nor on pyruvate". The Journal of Neuroscience. 31 (1): 34–45. doi:10.1523/JNEUROSCI.3314-10.2011. PMID 21209187.
- Ruusuvuori E, Kirilkin I, Pandya N, Kaila K (November 2010). "Spontaneous network events driven by depolarizing GABA action in neonatal hippocampal slices are not attributable to deficient mitochondrial energy metabolism". The Journal of Neuroscience. 30 (46): 15638–42. doi:10.1523/JNEUROSCI.3355-10.2010. PMID 21084619.
- Mukhtarov M, Ivanov A, Zilberter Y, Bregestovski P (January 2011). "Inhibition of spontaneous network activity in neonatal hippocampal slices by energy substrates is not correlated with intracellular acidification". Journal of Neurochemistry. 116 (2): 316–21. doi:10.1111/j.1471-4159.2010.07111.x. PMID 21083663.
- Ivanov A, Mukhtarov M, Bregestovski P, Zilberter Y (2011). "Lactate Effectively Covers Energy Demands during Neuronal Network Activity in Neonatal Hippocampal Slices". Frontiers in Neuroenergetics. 3: 2. doi:10.3389/fnene.2011.00002. PMC . PMID 21602909.
- Khakhalin AS (September 2011). "Questioning the depolarizing effects of GABA during early brain development". Journal of Neurophysiology. 106 (3): 1065–7. doi:10.1152/jn.00293.2011. PMID 21593390.
- Kirmse K, Kummer M, Kovalchuk Y, Witte OW, Garaschuk O, Holthoff K (July 2015). "GABA depolarizes immature neurons and inhibits network activity in the neonatal neocortex in vivo". Nature Communications. 6: 7750. Bibcode:2015NatCo...6E7750K. doi:10.1038/ncomms8750. PMID 26177896.
- Valeeva G, Tressard T, Mukhtarov M, Baude A, Khazipov R (June 2016). "An Optogenetic Approach for Investigation of Excitatory and Inhibitory Network GABA Actions in Mice Expressing Channelrhodopsin-2 in GABAergic Neurons". The Journal of Neuroscience. 36 (22): 5961–73. doi:10.1523/JNEUROSCI.3482-15.2016. PMID 27251618.
- Purves D, Fitzpatrick D, Hall WC, Augustine GJ, Lamantia AS, eds. (2007). Neuroscience (4th ed.). Sunderland, Mass: Sinauer. pp. 135, box 6D. ISBN 0-87893-697-1.
- Jelitai M, Madarasz E (2005). "The role of GABA in the early neuronal development". Int. Rev. Neurobiol. International Review of Neurobiology. 71: 27–62. doi:10.1016/S0074-7742(05)71002-3. ISBN 9780123668721. PMID 16512345.
- Marín O, Rubenstein JL (November 2001). "A long, remarkable journey: tangential migration in the telencephalon". Nat. Rev. Neurosci. 2 (11): 780–90. doi:10.1038/35097509. PMID 11715055.
- LoTurco JJ, Owens DF, Heath MJ, Davis MB, Kriegstein AR (December 1995). "GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis". Neuron. 15 (6): 1287–1298. doi:10.1016/0896-6273(95)90008-X. PMID 8845153.
- Haydar TF, Wang F, Schwartz ML, Rakic P (August 2000). "Differential modulation of proliferation in the neocortical ventricular and subventricular zones". J. Neurosci. 20 (15): 5764–74. PMC . PMID 10908617.
- Behar TN, Schaffner AE, Scott CA, O'Connell C, Barker JL (August 1998). "Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus". J. Neurosci. 18 (16): 6378–87. PMID 9698329.
- Barbin G, Pollard H, Gaïarsa JL, Ben-Ari Y (April 1993). "Involvement of GABAA receptors in the outgrowth of cultured hippocampal neurons". Neurosci. Lett. 152 (1–2): 150–154. doi:10.1016/0304-3940(93)90505-F. PMID 8390627.
- Maric D, Liu QY, Maric I, Chaudry S, Chang YH, Smith SV, Sieghart W, Fritschy JM, Barker JL (April 2001). "GABA expression dominates neuronal lineage progression in the embryonic rat neocortex and facilitates neurite outgrowth via GABA(A) autoreceptor/Cl− channels". J. Neurosci. 21 (7): 2343–60. PMID 11264309.
- Ben-Ari Y (September 2002). "Excitatory actions of gaba during development: the nature of the nurture". Nat. Rev. Neurosci. 3 (9): 728–739. doi:10.1038/nrn920. PMID 12209121.
- Obrietan K, Gao XB, Van Den Pol AN (August 2002). "Excitatory actions of GABA increase BDNF expression via a MAPK-CREB-dependent mechanism—a positive feedback circuit in developing neurons". J. Neurophysiol. 88 (2): 1005–15. PMID 12163549.
- Wang DD, Kriegstein AR, Ben-Ari Y (2008). "GABA regulates stem cell proliferation before nervous system formation". Epilepsy Curr. 8 (5): 137–9. doi:10.1111/j.1535-7511.2008.00270.x. PMC . PMID 18852839.
- Popp A, Urbach A, Witte OW, Frahm C (2009). Reh TA, ed. "Adult and embryonic GAD transcripts are spatiotemporally regulated during postnatal development in the rat brain". PLoS ONE. 4 (2): e4371. Bibcode:2009PLoSO...4.4371P. doi:10.1371/journal.pone.0004371. PMC . PMID 19190758.
- Erdö SL, Wolff JR (February 1990). "γ-Aminobutyric acid outside the mammalian brain". J. Neurochem. 54 (2): 363–72. doi:10.1111/j.1471-4159.1990.tb01882.x. PMID 2405103.
- Xiang YY, Wang S, Liu M, Hirota JA, Li J, Ju W, Fan Y, Kelly MM, Ye B, Orser B, O'Byrne PM, Inman MD, Yang X, Lu WY (July 2007). "A GABAergic system in airway epithelium is essential for mucus overproduction in asthma". Nat. Med. 13 (7): 862–7. doi:10.1038/nm1604. PMID 17589520.
- Payne AH, Hardy MH (2007). The Leydig cell in health and disease. Humana Press. ISBN 1-58829-754-3.
- Kwakowsky A, Schwirtlich M, Zhang Q, Eisenstat DD, Erdélyi F, Baranyi M, Katarova ZD, Szabó G (December 2007). "GAD isoforms exhibit distinct spatiotemporal expression patterns in the developing mouse lens: correlation with Dlx2 and Dlx5". Dev. Dyn. 236 (12): 3532–44. doi:10.1002/dvdy.21361. PMID 17969168.
- Ramesh SA, Tyerman SD, Xu B, Bose J, Kaur S, Conn V, Domingos P, Ullah S, Wege S, Shabala S, Feijó JA, Ryan PR, Gilliham M, Gillham M (2015). "GABA signalling modulates plant growth by directly regulating the activity of plant-specific anion transporters". Nat Commun. 6: 7879. Bibcode:2015NatCo...6E7879R. doi:10.1038/ncomms8879. PMC . PMID 26219411.
- Ramesh SA, Tyerman SD, Gilliham M, Xu B (2016). "γ-Aminobutyric acid (GABA) signalling in plants". Cell. Mol. Life Sci. doi:10.1007/s00018-016-2415-7. PMID 27838745.
- Majumdar D, Guha S (1988). "Conformation, electrostatic potential and pharmacophoric pattern of GABA (γ-aminobutyric acid) and several GABA inhibitors". Journal of Molecular Structure: THEOCHEM. 180: 125–140. doi:10.1016/0166-1280(88)80084-8.
- Sapse AM (2000). Molecular Orbital Calculations for Amino Acids and Peptides. Birkhäuser. ISBN 978-0-8176-3893-1.[page needed]
- Roth RJ, Cooper JR, Bloom FE (2003). The Biochemical Basis of Neuropharmacology. Oxford [Oxfordshire]: Oxford University Press. p. 106. ISBN 0-19-514008-7.
- Kuriyama K, Sze PY (January 1971). "Blood–brain barrier to H3-γ-aminobutyric acid in normal and amino oxyacetic acid-treated animals". Neuropharmacology. 10 (1): 103–108. doi:10.1016/0028-3908(71)90013-X. PMID 5569303.
- Petroff OA (December 2002). "GABA and glutamate in the human brain". Neuroscientist. 8 (6): 562–573. doi:10.1177/1073858402238515. PMID 12467378.
- Schousboe A, Waagepetersen HS (2007). "GABA: homeostatic and pharmacological aspects". Prog. Brain Res. Progress in Brain Research. 160: 9–19. doi:10.1016/S0079-6123(06)60002-2. ISBN 978-0-444-52184-2. PMID 17499106.
- Bown AW, Shelp BJ (September 1997). "The Metabolism and Functions of γ-Aminobutyric Acid". Plant Physiol. 115 (1): 1–5. doi:10.1104/pp.115.1.1. PMC . PMID 12223787.
- Foster AC, Kemp JA (February 2006). "Glutamate- and GABA-based CNS therapeutics". Curr Opin Pharmacol. 6 (1): 7–17. doi:10.1016/j.coph.2005.11.005. PMID 16377242.
- Chapouthier G, Venault P (October 2001). "A pharmacological link between epilepsy and anxiety?". Trends Pharmacol. Sci. 22 (10): 491–3. doi:10.1016/S0165-6147(00)01807-1. PMID 11583788.
- Campagna JA, Miller KW, Forman SA (May 2003). "Mechanisms of actions of inhaled anesthetics". N. Engl. J. Med. 348 (21): 2110–24. doi:10.1056/NEJMra021261. PMID 12761368.
- Müller EE, Locatelli V, Cocchi D (April 1999). "Neuroendocrine control of growth hormone secretion". Physiol. Rev. 79 (2): 511–607. PMID 10221989.
- Powers ME, Yarrow JF, McCoy SC, Borst SE (January 2008). "Growth hormone isoform responses to GABA ingestion at rest and after exercise". Medicine and science in sports and exercise. 40 (1): 104–10. doi:10.1249/mss.0b013e318158b518. PMID 18091016.
- Balemans MG, Mans D, Smith I, Van Benthem J (1983). "The influence of GABA on the synthesis of N-acetylserotonin, melatonin, O-acetyl-5-hydroxytryptophol and O-acetyl-5-methoxytryptophol in the pineal gland of the male Wistar rat". Reproduction, Nutrition, Development. 23 (1): 151–60. doi:10.1051/rnd:19830114. PMID 6844712.
- Dzitoyeva S, Dimitrijevic N, Manev H (2003). "γ-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in Drosophila: adult RNA interference and pharmacological evidence". Proc. Natl. Acad. Sci. U.S.A. 100 (9): 5485–5490. Bibcode:2003PNAS..100.5485D. doi:10.1073/pnas.0830111100. PMC . PMID 12692303.
- Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE, Mascia MP, Valenzuela CF, Hanson KK, Greenblatt EP, Harris RA, Harrison NL (1997). "Sites of alcohol and volatile anaesthetic action on GABAA and glycine receptors". Nature. 389 (6649): 385–389. Bibcode:1997Natur.389..385M. doi:10.1038/38738. PMID 9311780.
- Boehm SL, Ponomarev I, Blednov YA, Harris RA (2006). "From gene to behavior and back again: new perspectives on GABAAreceptor subunit selectivity of alcohol actions". Adv. Pharmacol. 54 (8): 1581–1602. doi:10.1016/j.bcp.2004.07.023. PMID 17175815.
- Dimitrijevic N, Dzitoyeva S, Satta R, Imbesi M, Yildiz S, Manev H (2005). "Drosophila GABAB receptors are involved in behavioral effects of gamma-hydroxybutyric acid (GHB)". Eur. J. Pharmacol. 519 (3): 246–252. doi:10.1016/j.ejphar.2005.07.016. PMID 16129424.
- Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT (August 2009). "Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity". Phytother Res. 23 (8): 1075–81. doi:10.1002/ptr.2712. PMID 19165747.
- Park DH, Mirabella R, Bronstein PA, Preston GM, Haring MA, Lim CK, Collmer A, Schuurink RC (October 2010). "Mutations in γ-aminobutyric acid (GABA) transaminase genes in plants or Pseudomonas syringae reduce bacterial virulence". Plant J. 64 (2): 318–30. doi:10.1111/j.1365-313X.2010.04327.x. PMID 21070411.
- Bouché N, Fromm H (March 2004). "GABA in plants: just a metabolite?". Trends Plant Sci. 9 (3): 110–5. doi:10.1016/j.tplants.2004.01.006. PMID 15003233.
- Roberts MR (September 2007). "Does GABA Act as a Signal in Plants?: Hints from Molecular Studies". Plant Signal Behav. 2 (5): 408–9. doi:10.4161/psb.2.5.4335. PMC . PMID 19704616.
|This section is empty. You can help by adding to it. (October 2016)|
- Media related to Gamma-Aminobutyric acid at Wikimedia Commons
- Parviz M, Vogel K, Gibson KM, Pearl PL (2014-11-25). "GABA". Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies. Journal of Pediatric Epilepsy. 3 (4): 217–227. doi:10.3233/PEP-14097. PMC . PMID 25485164.
Clinical disorders known to affect inherited GABA metabolism
- Gamma-aminobutyric acid MS Spectrum
- Scholarpedia article on GABA
- List of GABA neurons on NeuroLex.org